<code id='0725B5196E'></code><style id='0725B5196E'></style>
    • <acronym id='0725B5196E'></acronym>
      <center id='0725B5196E'><center id='0725B5196E'><tfoot id='0725B5196E'></tfoot></center><abbr id='0725B5196E'><dir id='0725B5196E'><tfoot id='0725B5196E'></tfoot><noframes id='0725B5196E'>

    • <optgroup id='0725B5196E'><strike id='0725B5196E'><sup id='0725B5196E'></sup></strike><code id='0725B5196E'></code></optgroup>
        1. <b id='0725B5196E'><label id='0725B5196E'><select id='0725B5196E'><dt id='0725B5196E'><span id='0725B5196E'></span></dt></select></label></b><u id='0725B5196E'></u>
          <i id='0725B5196E'><strike id='0725B5196E'><tt id='0725B5196E'><pre id='0725B5196E'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:comprehensive    Page View:1
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more
          How many hemophilia patients actually want gene therapy?
          How many hemophilia patients actually want gene therapy?

          AdobeAsaboygrowingupwithhemophiliaA,NoahFrederickreservedtheendofhisannualcheckupstotalkaboutnewtech

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          John Green on his newest strategy for fighting tuberculosis

          JohnGreen:"Ididn'tunderstandthattuberculosisisthispresent-tensecatastrophe."MarinaWatersWASHINGTON—J